Anula Jayasuriya

Founder & Managing Director, EXXclaim Capital; Co-founder EILSF, Los Altos Hills, California, USA

Anula Jayasuriya is a successful private equity executive and venture capitalist whose background combines deep business, scientific and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience.

In 2013, Anula founded EXXclaim Capital, an early stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health. EXXclaim’s first investment, nVision Medical, was acquired in 2018 by Boston Scientific Inc. for $275 Million, validating the significant business opportunity in women’s health.

In 2006 Anula co-founded the “Evolvence India Life Science Fund” (www.invascent.com), the very first fund in India to focus exclusively on health care and invest in Indian pharmaceutical, biotechnology, medical device and contract services companies. The fund garnered attractive returns to investors.

Anula was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP Business Development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation.

Anula serves on the boards of several biotechnology companies, and also serves non-profit boards.

Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also holds a M. Phil. in pharmacology from the University of Cambridge, in England.